Efavirenz interference in estradiol ELISA assay.
Efavirenz interference in estradiol ELISA assay.
复制标题
DOI：
10.1093/clinchem/46.5.734
复制
发表时间：
2000-05
影响因子：
9.3
通讯作者：
A. Sinicco;R. Raiteri;A. Rossati;A. Savarino;G. di Perri
中科院分区：
文献类型：
--
作者：
A. Sinicco;R. Raiteri;A. Rossati;A. Savarino;G. di Perri
The prognosis of HIV infection has dramatically changed following the introduction of highly active antiretroviral therapy (HAART), a multidrug regimen usually consisting of three to four antiretroviral drugs belonging to the categories of nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs) and of protease inhibitors (PIs). The somewhat remarkable therapeutic properties of these regimens are often associated to some degree of toxicity and side effects, also resulting from drug interactions. These occur both among antiretrovirals and between the latter and unrelated compounds (1), thus implying some restriction in the use of various drugs in several clinical circumstances. The novel NNRTI efavirenz, a drug exerting an intrinsic antiretroviral activity of the same order of magnitude as PIs (2), was found to increase by 37% the area under the curve of coadministered ethinyl estradiol (3), an effect thought to result from interaction with cytochrome P450. In a …
